ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,938Medicare Part D Prescriptions Filled, Including Refills

Rank: 41 out of 663

$403K Total Retail Price of All Prescriptions

Rank: 131 out of 663

704 Patients Receiving at Least One Drug in Part D
90%Patients 65 Years and Older
13% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Colorado
Lower avg

Schedule Two
Controlled Substances

7% of this provider’s 704 patients filled at least one prescription for a schedule two drug, compared to an average of 8%.

Schedule Three
Controlled Substances

10% of this provider’s 704 patients filled at least one prescription for a schedule three drug, compared to an average of 9%.

Risky Drugs to Seniors

2% of this provider’s 9,955 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$37 was the average price of a prescription from this provider, compared to $56 among peers.

Prescriptions per Patient

16 is the average number of prescriptions (including refills) per patient, compared to an average of 15.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Colorado
SIMVASTATIN 1,001 927 1 1
LISINOPRIL 528 453 2 2
OMEPRAZOLE 517 477 3 4
ATENOLOL 435 404 4 10
LEVOTHROID 419 397 10 5 19
AMLODIPINE BESYLATE 401 388 6 5
LOSARTAN POTASSIUM 334 322 7 14
LISINOPRIL-HYDROCHLOROTHIAZIDE 314 282 8 22
LEVOTHYROXINE SODIUM 301 287 9 3
METFORMIN HCL 300 245 10 9
ALENDRONATE SODIUM 292 283 11 15
WARFARIN SODIUM 244 228 12 8
METOPROLOL TARTRATE 219 203 13 11
FUROSEMIDE 206 194 14 7
HYDROCODONE-ACETAMINOPHEN 202 161 S3 15 6
K-TAB 196 191 16 36
HYDROCHLOROTHIAZIDE 192 168 17 12
NOVOLIN N 166 138 18 44
GLIPIZIDE 162 151 19 29
TRAMADOL HCL 156 135 20 17
RANITIDINE HCL 153 143 21 31
ATORVASTATIN CALCIUM 136 120 22 13
INSULIN SYRINGE 132 114 23 55
TRIAMTERENE-HYDROCHLOROTHIAZID 126 126 24 49
MIRTAZAPINE 122 121 25 52
PROAIR HFA 111 105 26 33
ESTRADIOL 107 95 R 27 66
NORTRIPTYLINE HCL 105 88 28 63
FLUOXETINE HCL 96 93 29 32
TRAZODONE HCL 95 82 30 34
OXYCODONE-ACETAMINOPHEN 93 64 S2 31 26
GABAPENTIN 90 58 32 20
FLUTICASONE PROPIONATE 90 86 32 27
ZOLPIDEM TARTRATE 82 76 34 16
CITALOPRAM HBR 81 67 35 18
LOVASTATIN 80 80 36 30
TAMSULOSIN HCL 76 75 37 24
PRAVASTATIN SODIUM 72 70 38 21
NOVOLIN R 71 48 39 106
ALLOPURINOL 69 68 40 28
TERAZOSIN HCL 59 59 41 38
SPIRIVA 51 50 42 62
PROPRANOLOL HCL 50 50 43 120
TRIAMTERENE-HCTZ 50 50 43 42
PREDNISONE 50 46 43 39
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Nov. 21, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.